Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

Carcinoma, Hepatocellular

Colorectal Neoplasms, Neoplasm, Residual

Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal Metastasis

Colorectal Neoplasms

Recurrence, Lymphoma, Extranodal NK-T-Cell

Gastrointestinal Neoplasms, Pancreatic Neoplasms

Skin Neoplasms

Small Cell Lung Carcinoma

Carcinoma, Hepatocellular

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Hodgkin Disease

Pathologic Complete Response, Rectal Neoplasms

Colorectal Neoplasms

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Esophageal Squamous Cell Carcinoma

Carcinoma, Non-Small-Cell Lung

Colorectal Neoplasms

Lymphoma, Follicular

Carcinoma, Hepatocellular

Advanced Solid Tumor

Nasopharyngeal Carcinoma

Carcinoma, Non-Small-Cell Lung

Nasopharyngeal Neoplasms

Squamous Cell Carcinoma of External Auditory Canal

Biliary Tract Neoplasms

Carcinoma, Hepatocellular

Lymphatic Metastasis

Tongue Squamous Cell Carcinoma

Neoplasm Metastasis

Pseudomyxoma Peritonei

Locally Advanced Rectal Carcinoma

Esophageal Squamous Cell Carcinoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Hepatocellular, Liver Neoplasms

Head and Neck Neoplasms

Squamous Cell Carcinoma of Head and Neck

Gastric Cancer Peritoneal Metastases

Colorectal Neoplasms

Muscle Invasive Bladder Cancer (MIBC)

Adenocarcinoma Of Esophagus, Stomach Neoplasms

Colorectal Neoplasms

Lung Neoplasms

Hodgkin Disease, Lymphoma

Prostatic Neoplasms

Insulin-Like Growth Factor I, Resistance To, Neoplasm Metastasis, Prostatic Neoplasms

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure

Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Modified Short-Course Radiotherapy Combined With Immunochemotherapy and Targeted Therapy as First-Line Treatment for MSS Metastatic Colorectal Cancer

LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis

EpiRev-NKT

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer

A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence

Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC

HOVON164HL

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

TRIUNITE06

Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

FMT-LUNG

Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma

Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors

Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma

Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal

Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTC

Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC

Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer

ATARI-PDAC

Pseudovax

A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer

TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy

Endosurgery-02

Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer

FRONT-1

Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma

A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.

A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10

FUTURE

HARBOR

NeoTISLEGA

Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer

FIL_Tisle-HL

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)